Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Health Equity PHGKB

Specific PHGKB|Economic Evaluation PHGKB|Public Health Genomics and Precision Health Knowledge Base (PHGKB)
Effective August 1, 2024, this database was discontinued. All content will remain searchable and be preserved online for historical purposes only until 2029.

spot light Spotlight

Wilson and Jungner Revisited: Are Screening Criteria Fit for the 21st Century?

From the abstract: "This systematic review revealed a set of general limitations of the WJ criteria, such as imprecise terminology, lack of measurability and objectivity, missing pediatric focus, and absent guidance on program management. Furthermore, it unraveled specific aspects of criticism on clinical, diagnostic, therapeutic, and economical aspects. A major obstacle was found to be the incompletely understood natural history and phenotypic diversity of rare diseases prior to NBS implementation, resulting in uncertainty about case definition, risk stratification, and indications for treatment. This gap could be closed through the systematic collection and evaluation of real-world evidence on the quality, safety, and (cost-)effectiveness of NBS, as well as the long-term benefits experienced by screened individuals. "

Health Care Costs After Genome-Wide Sequencing for Children With Rare Diseases in England and Canada

From the abstract: "Is diagnosis from genome-wide sequencing associated with reduced health care costs for children with suspected rare diseases? Findings: In this cohort study of 3 groups of children who underwent genome-wide sequencing in England (7775 children in a research study) or Canada (118 children who received publicly funded sequencing and 77 children in a research study), diagnosis from genome-wide sequencing was not associated with changes in health care or diagnostic costs. Meaning: These findings suggest that sustainable clinical implementation of genome-wide sequencing must be motivated by evidence of patient and family benefit and cost-effectiveness rather than promises of cost savings from earlier diagnosis. "

Systematic reanalysis of genomic data by diagnostic laboratories: a scoping review of ethical, economic, legal and (psycho)social implications.
Marije A van der Geest et al. Eur J Hum Genet 2024 3

From the abstract: "In total, we identified nine ELSI aspects, such as (perceived) professional responsibilities, implications for consent and cost-effectiveness. The identified ELSI aspects brought forward necessary trade-offs for GHPs to consciously take into account when considering responsible implementation of systematic reanalysis of NGS data in routine diagnostics, balancing the various strains on their laboratories and personnel while creating optimal results for new and former patients. "

Improving Noninvasive Colorectal Cancer Screening.
John M Carethers et al. N Engl J Med 2024 3 (11) 1045-1046

From the article: "Screening for colorectal cancer saves lives. Screening tests have evolved to include stool-based, endoscopic and image-based, and blood-based methods, with minimal thresholds for sensitivity and specificity for colorectal cancer set by the baseline characteristics of FIT. Although multiple tests have been developed over time and vary in cost-effectiveness for colorectal cancer screening, the best screening test is the one that gets completed by the patient. Most of the recommended tests, including the two newer tests assessed in the studies now published in the Journal, improve on the sensitivity and approach the specificity of FIT. "


news Latest News and Publications
Cost-Utility Analysis of Supervised Inspiratory Muscle Training Added to Post-COVID Rehabilitation Program in the Public Health System of Brazil. External Web Site Icon
Modesto Guilherme Pacheco, et al. International journal of environmental research and public health 2024 0 0. (11)
From Sequence to System: Enhancing IVT mRNA Vaccine Effectiveness through Cutting-Edge Technologies. External Web Site Icon
Xu Lifeng, et al. Molecular pharmaceutics 2024 0 0.
Advancements in LAMP-Based Diagnostics: Emerging Techniques and Applications in Viral Detection with a Focus on Herpesviruses in Transplant Patient Management. External Web Site Icon
Gomes Torres Ana Cláudia Martins Braga, et al. International journal of molecular sciences 2024 0 0. (21)
What COVID-19 Vaccination Strategy Should Be Implemented and Which Vaccines Should Be Used in the Post-Pandemic Era? External Web Site Icon
Plans-Rubió Pedro, et al. Vaccines 2024 0 0. (10)
In Silico Identification of Potential Inhibitors of SARS-CoV-2 Main Protease (M). External Web Site Icon
Hernández-Serda Manuel Alejandro, et al. Pathogens (Basel, Switzerland) 2024 0 0. (10)
SARS-CoV-2 variant survey: Comparison of RT-PCR screening with TGS and variant distribution across two divisions of Bangladesh. External Web Site Icon
Kawser Zannat, et al. PloS one 2024 0 0. (10) e0311993
Exploring online public survey lifestyle datasets with statistical analysis, machine learning and semantic ontology. External Web Site Icon
Chatterjee Ayan, et al. Scientific reports 2024 0 0. (1) 24190
Clinical and cost-effectiveness of remote-delivered, online lifestyle therapy versus psychotherapy for reducing depression: results from the CALM non-inferiority, randomised trial. External Web Site Icon
O'Neil Adrienne, et al. The Lancet regional health. Western Pacific 2024 0 0. 101142
A six-compartment model for COVID-19 with transmission dynamics and public health strategies. External Web Site Icon
Ambalarajan Venkatesh, et al. Scientific reports 2024 0 0. (1) 22226
Early mathematical models of COVID-19 vaccination in high-income countries: a systematic review. External Web Site Icon
Burch E, et al. Public health 2024 0 0. 207-215

More

About Economic Evaluation PHGKB

Economic Evaluation PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that identify, measure, value, and compare the costs and consequences of genomic and other precision health interventions, policies and programs. Economic Evaluation PHGKB is a specialized database of the overall PHGKB.

Content Summary

Quick Links


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP